v3.26.1
Business segment information (Tables)
6 Months Ended
Jun. 27, 2026
Business segment information  
Segment revenue reconciles to statutory revenues from continuing operations

  ​ ​ ​

27 June

  ​ ​ ​

28 June

2026

2025

$m

$m

Reportable segment revenue

 

  ​

 

  ​

Sports Medicine & ENT

1,017

923

Advanced Wound Management

867

845

Orthopaedics

1,213

1,193

Revenue from external customers

3,097

2,961

Disaggregation of revenue

  ​ ​ ​

27 June

  ​ ​ ​

28 June

Revenue by product from continuing operations

2026

2025

$m 

$m 

Sports Medicine Joint Repair

 

574

 

509

Arthroscopic Enabling Technologies

 

340

 

307

ENT (Ear, Nose and Throat)

103

 

107

Sports Medicine & ENT

 

1,017

 

923

Advanced Wound Care

 

398

 

366

Advanced Wound Bioactives

 

263

 

285

Advanced Wound Devices

 

206

 

194

Advanced Wound Management

 

867

 

845

Knee Implants

 

492

 

501

Hip Implants

 

326

 

313

Other Reconstruction

 

68

 

64

Trauma & Extremities

 

327

 

315

Orthopaedics

 

1,213

 

1,193

Total

 

3,097

 

2,961

27 June 2026

28 June 2025

Established
MarketsE

Emerging
Markets

Total

Established
MarketsE

Emerging
Markets

Total

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

Orthopaedics, Sports Medicine & ENT

1,810

420

2,230

1,752

364

2,116

Advanced Wound Management

739

128

867

731

114

845

Total

2,549

 

548

3,097

2,483

 

478

2,961

E

Established Markets comprises US, Australia, Canada, Europe, Japan and New Zealand.

Trading profit reconciles to operating profit

27 June

28 June

2026

2025

  ​ ​ ​

$m

  ​ ​ ​

$m

Segment profit

Sports Medicine & ENT

 

251

213

Advanced Wound Management

 

191

187

Orthopaedics

 

158

151

Segment trading profit

 

600

551

Corporate costs1

(34)

(28)

Acquisition and disposal related items

(21)

(9)

Restructuring and rationalisation expenses

(23)

(8)

Amortisation and impairment of acquisition intangibles

(87)

(83)

Legal and other

 

13

6

Operating profit

 

448

429

Interest income

10

15

Interest expense

(65)

(69)

Other finance costs

(18)

(12)

Share of results of associates

5

(1)

Profit before taxation

380

362

1

Corporate costs include centralised infrastructure costs such as compliance and group functions.

Schedule of depreciation and amortisation included in segment profit

27 June

28 June

2026

2025

  ​ ​ ​

$m

  ​ ​ ​

$m

Depreciation and amortisation

Sports Medicine & ENT

55

51

Advanced Wound Management

37

34

Orthopaedics

115

112